Reed Jobs would rather talk about curing cancer than his last name
Article summary
Quick briefing — cleaned from the original RSS feed
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs's words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.
1Key Takeaways
- When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash.
- Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs's words, a huge part of what Yosemite does.
- "I didn't expect Yosemite to be moving this fast," he said.
2AIWedia Score
9.8/10
Must-read — high impact for AI builders
Based on source trust, recency, category impact, and story depth.
3Why it matters
Funding rounds show which AI bets investors back—and which categories may scale quickly. TechCrunch Venture reports that when we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash.
Explore related
Browse toolsRelated tools
Funding news
Explore curated funding tools on AIWedia — compare, rank, and launch from our directory.
Full story on TechCrunch Venture
Read full articleHeadlines aggregated via RSS for discovery on AIWedia. Original content © TechCrunch Venture. We link to the source and do not republish full articles.